Posted by Michael Wonder on 14 May 2019
FDA approves Eylea (aflibercept) injection for diabetic retinopathy
13 May 2019 - Eylea improves diabetic retinopathy and prevents worsening disease that can lead to blindness.
Regeneron Pharmaceuticals today announced that the U.S. FDA has approved Eylea (aflibercept) Injection to treat all stages of diabetic retinopathy and thereby reduce the risk of blindness.
"Millions of people have been robbed of their vision due to the progression of diabetic retinopathy," said David Brown, M.D., F.A.C.S., an investigator for the PANORAMA trial and Director of Research at Retina Consultants of Houston. "The prevention of worsening diabetic retinopathy with Eylea provides a compelling rationale for early treatment of patients with this disease, particularly since eyes dosed with Eylea as infrequently as every 16 weeks showed significant improvements in the pivotal PANORAMA trial."
